KPMG has announced that Caroline Boulliat has joined its UK firm as a partner to lead relationships for pharma clients headquartered in Europe, Middle East and Africa.
Boulliat, who will work in the firm’s Life Sciences department, has more than 20 years’ experience in the pharma industry, most recently running her own consulting practice after leaving biotechnology company Amgen in 2019.
She started her career as a hospital pharmacist before taking a Masters in marketing. Boulliait also embarked on a “global career with a commercial focus on innovative drugs and biosimilar brands including Pfizer, GSK, MSD and Amgen”.
In her new role, she states that she will “help clients adapt for the future and show how things can be done differently post-covid”.
She said: “Our clients are facing a double-hit thanks to Covid. Sales reps can’t access the hospitals to share news of the latest advances, and trials have been severely impeded. Beyond Covid, of course there’s the complexities presented by Brexit – from supply chain management, to talent attraction and retention.”
Adrian Griffiths, head of life sciences at KPMG, added: “The next 12 months in particular will be a challenging time for the industry, and we are delighted to have Caroline on board. She will play an essential part in working with clients to really understand their issues and how KPMG can support them.”